SGMO News and Press, Sangamo Therapeutics Inc. From 01/06/21

Sangamo Therapeutics (SGMO) announces today that CFO Sung Lee is leaving the company to pursue a new opportunity overseas. Mr. Lee’s last day of employment will be February 1, 2021.“Sung has contributed significantly to Sangamo’s evolution, helping us build...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s last day of employment will be February 1, 2021. “Sung has contributed si...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 th at 5:20pm EST. The virtual session will be webcast live ...

AVROBIO is developing gene therapies for lysosomal disorders where lifelong enzyme replacement therapy is the SoC. Early stage data shows promise. If successful, it is looking at a multibillion dollar market. For further details see: AVROBIO: Undercovered Gene Therapy De...

Sangamo spent three years building their genomic medicines platform, pipeline and in-house manufacturing capabilities while saying they were not interested in being acquired. The pipeline is not broad and deep with lead assets poised to validate the underlying platforms. Several o...

What Are The Top Biotech Stocks To Buy Ahead Of 2021? Biotech stocks have been especially hot in the stock market this year. In fact, they have been the go-to stocks for investors looking towards high-risk, high-reward sectors. Undeniably, the race for a coronavirus vaccine ...

Pfizer (PFE) and Sangamo Therapeutics (SGMO) report that giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A, demonstrated sustained factor VIII activity levels in high dose 3 x 1013 vg/kg cohort.All five patients in ...

- First patient was dosed in pivotal Phase 3 AFFINE study in October 2020 Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (...

Pfizer has been working on New Pfizer for almost a decade. The spin offs of Consumer Health and Upjohn appear to be the last steps. Continuation of the policy of dividend growth is a stated priority. Biopharma led by scientific pipeline innovation is expected to generate $15 ...

Gene regulation targeted at RNA or DNA has enormous potential for previously intractable nervous system disorders. Allele-specific gene regulation is a more precise approach targeting only the mutant gene tied to diseases such as ALS and Huntington's. DNA-targeted therapies are po...